The pharmacokinetics and pharmacodynamics of iron preparations.
about
The role of ferric carboxymaltose in the treatment of iron deficiency anemia in patients with gastrointestinal diseaseAnemia and iron deficiency in gastrointestinal and liver conditionsIron therapy for the treatment of iron deficiency in chronic heart failure: intravenous or oral?Iron Therapy in Patients with Heart Failure and Iron Deficiency: Review of Iron Preparations for Practitioners.Protein Hydrolysates as Promoters of Non-Haem Iron Absorption.Efficacy, Tolerability, and Acceptability of Iron Hydroxide Polymaltose Complex versus Ferrous Sulfate: A Randomized Trial in Pediatric Patients with Iron Deficiency Anemia.Optimizing iron delivery in the management of anemia: patient considerations and the role of ferric carboxymaltose.Ferrous sulfate, but not iron polymaltose complex, aggravates local and systemic inflammation and oxidative stress in dextran sodium sulfate-induced colitis in rats.Intravenous Iron Therapy in Patients with Iron Deficiency Anemia: Dosing Considerations.Intravenous Iron Carboxymaltose as a Potential Therapeutic in Anemia of Inflammation.Modeling the dynamics of mouse iron body distribution: hepcidin is necessary but not sufficientClinical iron deficiency disturbs normal human responses to hypoxia.Comparison of the Efficacies of Parenteral Iron Sucrose and Oral Iron Sulfate for Anemic Patients with Inflammatory Bowel Disease in KoreaIron Therapy Challenges for the Treatment of Nondialysis CKD PatientsIron deficiency or anemia of inflammation? : Differential diagnosis and mechanisms of anemia of inflammationIron deficiency in cancer patients.Ferric carboxymaltose.Pharmacokinetics of Ferric Pyrophosphate Citrate, a Novel Iron Salt, Administered Intravenously to Healthy Volunteers.Ferumoxytol: in iron deficiency anaemia in adults with chronic kidney disease.The science and practice of micronutrient supplementations in nutritional anemia: an evidence-based review.Iron sucrose - characteristics, efficacy and regulatory aspects of an established treatment of iron deficiency and iron-deficiency anemia in a broad range of therapeutic areas.Heme iron polypeptide for the management of anaemia of chronic kidney disease.Distinct immunologic effects of different intravenous iron preparations on monocytesNovel iron-containing phosphate binders and anemia treatment in CKD: oral iron intake revisited.Use of iron sucrose and red blood cell transfusions in anaemic cancer patients in France (OncoFer study).Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and management.Towards Holistic Heart Failure Management-How to Tackle the Iron Deficiency Epidemic?Ferric carboxymaltose-mediated attenuation of Doxorubicin-induced cardiotoxicity in an iron deficiency rat model.Safety of intravenous ferric carboxymaltose versus oral iron in patients with nondialysis-dependent CKD: an analysis of the 1-year FIND-CKD trial.Porphyria Cutanea Tarda in a Patient with End-Stage Renal Disease: A Case of Successful Treatment with Deferoxamine and Ferric Carboxymaltose.Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells.Ferrous iron content of intravenous iron formulations.Physico-chemical properties of the new generation IV iron preparations ferumoxytol, iron isomaltoside 1000 and ferric carboxymaltose.Markers of oxidative/nitrosative stress and inflammation in lung tissue of rats exposed to different intravenous iron compounds.Novel Iron-Whey Protein Microspheres Protect Gut Epithelial Cells from Iron-Related Oxidative Stress and Damage and Improve Iron Absorption in Fasting Adults.How to select a nanosimilar.Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice.Determination of Non-Transferrin Bound Iron, Transferrin Bound Iron, Drug Bound Iron and Total Iron in Serum in a Rats after IV Administration of Sodium Ferric Gluconate Complex by Simple Ultrafiltration Inductively Coupled Plasma Mass SpectrometricVery low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.Iron deficiency in chronic heart failure: case-based practical guidance
P2860
Q26771882-F9C455F5-7E90-484F-AEB5-731F83476289Q28069820-63D81F38-2133-4A52-95E4-C0C3E80E6FFFQ28088503-1CCFF59F-1E53-4E01-A34E-3357DB347242Q33700880-2D8D7E86-B27D-4782-B1AD-31C739DBC96FQ33852080-66EDBFCA-DCC8-4F04-812A-0723912E1125Q34029552-A4CC746C-B6AE-4545-8D75-328A3E12DE26Q34700903-690A7D01-8527-46AB-8404-8F51A9EEA820Q35596454-08B646C7-F342-4964-90F9-89B0199060AAQ35898038-F9F077B0-B6D3-469B-930C-C3FB2D4A6CB9Q36073896-516ED827-3887-4097-B64A-E12AC66667B2Q36375897-22BD3AD4-B872-4B04-B8B2-A4DF41010695Q36951774-42DE7203-380D-4710-B217-446EBAE88B57Q37066370-25F3B479-F66D-4CA8-9B1C-EED174D345CAQ37069943-758EEF60-FA2F-40F0-B78B-620176B1FEB3Q37341829-BDACF1B5-FD74-4AEB-B68A-F848E657BEBAQ37429231-2F1B6221-4197-48A6-B085-87C3682C314BQ37460956-16C1F334-71E5-4AF3-B2C2-723C2749FFDFQ37664189-015108DE-86D7-40D3-9543-C9D1F7BC7B2FQ38044987-6C0ABF9A-C581-4E46-9E91-94F6CFD634A5Q38213371-EEB2B5DE-1594-48E3-8A24-1711AE57D773Q38245887-F868FAC5-96D2-4643-BB35-5BFD9756E296Q38466363-9C2FDE78-3798-4FE7-95C1-E082ABA0DC2BQ38541320-FF0A3650-DD4D-406F-8968-8CF719F154BCQ38542710-2A8E1F6E-3EF2-4611-B740-B79FEB97D34EQ39132837-5AA62EBF-A578-4491-9224-54687C18CAF0Q39371536-EA0884B6-3E71-44CA-A931-03250C388422Q39409288-DE688E6C-2ECE-46CC-9BE6-399CE163BA2EQ39642839-D442FB68-B567-48BD-88EA-D154E7D1637FQ40279708-04554861-D0DE-4431-A906-28F1FB6B722EQ40328644-D22AD819-484A-4D18-990E-86B44FB059F9Q40469488-5B50821C-1BCB-4185-87C6-A591E71A32ABQ40762942-7612EF17-C16D-4945-B2F6-B0278611808FQ41173473-B4B9AC6D-B844-4014-97BB-F276AC83C882Q41282906-A60CB675-2697-443F-8654-9097EF091DD1Q47232455-48E9A849-EF98-403C-B5C2-436C61A695BCQ47762210-BB066657-2B93-4CC6-A2F4-8FFD7C6F63F6Q47821861-ED8A9BD3-FC1C-4399-AB0D-2F972B08CAEBQ50034053-B50F5744-CDE2-49A1-932E-709994A4D074Q53823548-FC9A0D97-2B33-448F-86FE-BEBFF03749CAQ56968591-FB835EA5-BFD2-4E2F-9451-95A744EAB5A1
P2860
The pharmacokinetics and pharmacodynamics of iron preparations.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
The pharmacokinetics and pharmacodynamics of iron preparations.
@ast
The pharmacokinetics and pharmacodynamics of iron preparations.
@en
The pharmacokinetics and pharmacodynamics of iron preparations.
@nl
type
label
The pharmacokinetics and pharmacodynamics of iron preparations.
@ast
The pharmacokinetics and pharmacodynamics of iron preparations.
@en
The pharmacokinetics and pharmacodynamics of iron preparations.
@nl
prefLabel
The pharmacokinetics and pharmacodynamics of iron preparations.
@ast
The pharmacokinetics and pharmacodynamics of iron preparations.
@en
The pharmacokinetics and pharmacodynamics of iron preparations.
@nl
P2860
P1433
P1476
The pharmacokinetics and pharmacodynamics of iron preparations.
@en
P2093
Peter Geisser
Susanna Burckhardt
P2860
P356
10.3390/PHARMACEUTICS3010012
P577
2011-01-04T00:00:00Z